Lidocaine

Lidocaine Full Name

Lidocaine

Lidocaine Introduction

Pain control, surgical recovery, and inflammation management remain major challenges in clinical medicine, and researchers continue to explore pharmacological targets that can safely regulate neural signaling and immune responses. One of the most widely studied compounds in this area is lidocaine, a classical local anesthetic whose primary molecular targets include voltage-gated sodium channels (particularly Nav1.7, Nav1.8, and other Nav family members). By blocking these channels in neuronal membranes, lidocaine stabilizes the inactive state of sodium channels and prevents rapid sodium influx during depolarization. This inhibition suppresses the initiation and propagation of action potentials in peripheral nerves, thereby reducing pain transmission. Because abnormal sodium channel activity is implicated in neuropathic pain and hyperexcitability disorders, these channels represent critical therapeutic targets in both anesthesiology and neuropharmacology. In addition to its anesthetic function, lidocaine is also classified as a class Ib antiarrhythmic agent, where its ability to selectively inhibit sodium currents in cardiac tissues helps correct abnormal electrical conduction and ventricular arrhythmias.

Beyond its classical role in sodium channel blockade, modern molecular studies have revealed that lidocaine interacts with multiple inflammatory and immune-related signaling pathways, expanding its relevance as a biological target modulator. Research has demonstrated that lidocaine can suppress Toll-like receptor (TLR) signaling and inhibit activation of the NF-κB pathway, a central regulator of inflammatory gene expression. Through these mechanisms, the drug reduces the release of pro-inflammatory mediators such as HMGB1, TNF-α, and IL-6, which are frequently elevated during tissue injury, surgery, and systemic inflammation. Lidocaine has also been reported to influence purinergic receptors such as P2X7, which are involved in microglial activation and neuroinflammatory responses. These molecular interactions provide a mechanistic explanation for the anti-inflammatory and immunomodulatory effects observed during intravenous lidocaine infusion in perioperative settings. Clinically, this translates into reduced inflammatory stress, improved postoperative pain control, and faster recovery after minimally invasive procedures.

Increasingly, researchers are investigating lidocaine-related targets in the context of disease progression, particularly in cancer biology and chronic inflammatory conditions. Experimental studies in breast cancer and other tumor models suggest that lidocaine may influence tumor cell behavior by regulating the expression and activity of voltage-gated sodium channels that are often overexpressed in metastatic cancer cells. By modulating these channels and affecting downstream signaling pathways, lidocaine has been shown to inhibit tumor cell proliferation, migration, and invasion in preclinical models. Additionally, emerging evidence indicates that lidocaine may influence epigenetic regulation and cellular stress pathways, further contributing to its potential anti-tumor and tissue-protective effects. These findings highlight the growing recognition that lidocaine is not only a traditional anesthetic but also a multifunctional pharmacological agent with diverse molecular targets relevant to pain management, inflammation control, cardiovascular disorders, and potentially cancer therapy.

Alternate Names for Lidocaine

2 Diethylamino N 2 6 dimethylphenyl acetamide; Acetamide 2-(diethylamino)-N-(26-dimethylphenyl); Lidocaine; INN; Anbesol; Anestacon; Broncaine; Cappicaine; Cito optadren; Cuivasil

• 1.Karnina R, et al.; Molecular mechanisms of lidocaine. Ann Med Surg (Lond). 2021, 69:102733.
  2.Matos AC, et al.; The Potential Effect of Lidocaine, Ropivacaine, Levobupivacaine and Morphine on Breast Cancer Pre-Clinical Models: A Systematic Review. Int J Mol Sci. 2022, 23(3):1894.